“Even in the earlier stages of PDAC, these markers are about 91% accurate. And when we use them together with CA 19-9, accuracy improves.”
MicroRNA Liquid Biopsy Panel Achieves 97% Accuracy for Pancreatic Cancer Early Detection Read More »
SOUND trial shows omitting sentinel node biopsy is safe in small breast cancers with negative axillary ultrasound—98% survival at 5 years.
TMT was not cost-effective at 5-year (ICER, $464,291 per QALY) or 10-year (ICER, $308,638 per QALY) time horizons despite improved quality of life.
EOCRC exhibited significantly higher TMB compared with LOCRC in hypermutated tumors, with distinct gene mutation patterns including elevated APC and KRAS.
FDA expands Pluvicto for earlier use while PARP inhibitors show benefit in BRCA1/2+ patients, advancing precision prostate cancer care.
Zongertinib becomes first oral HER2-targeted therapy for NSCLC, achieving 75% response rate in previously treated patients.
